DexCom (NASDAQ:DXCM) has been assigned a $150.00 target price by investment analysts at Oppenheimer in a research report issued on Thursday. The brokerage presently has a “buy” rating on the medical device company’s stock. Oppenheimer’s price target indicates a potential upside of 23.55% from the company’s current price.
Other equities analysts have also issued research reports about the company. BidaskClub raised DexCom from a “hold” rating to a “buy” rating in a research note on Saturday, November 10th. Northland Securities raised DexCom from an “under perform” rating to a “market perform” rating in a research note on Wednesday, September 12th. Jefferies Financial Group increased their price target on DexCom to $148.00 and gave the stock a “buy” rating in a report on Wednesday, November 7th. Stephens increased their price target on DexCom from $170.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, November 7th. Finally, Piper Jaffray Companies increased their price objective on DexCom to $157.00 and gave the stock an “overweight” rating in a report on Wednesday, November 7th. Nine research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $132.65.
Shares of DexCom stock opened at $121.41 on Thursday. The stock has a market cap of $11.50 billion, a PE ratio of -209.33 and a beta of 0.55. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.71 and a quick ratio of 4.43. DexCom has a 52-week low of $51.04 and a 52-week high of $152.14.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, November 6th. The medical device company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.29. The company had revenue of $266.70 million during the quarter, compared to analyst estimates of $242.72 million. DexCom had a negative return on equity of 2.89% and a net margin of 4.72%. DexCom’s revenue for the quarter was up 44.5% on a year-over-year basis. Equities analysts expect that DexCom will post -0.13 earnings per share for the current fiscal year.
In related news, EVP Steven Robert Pacelli sold 3,114 shares of the firm’s stock in a transaction dated Monday, September 24th. The stock was sold at an average price of $141.25, for a total value of $439,852.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 25,495 shares of the firm’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $143.62, for a total transaction of $3,661,591.90. The disclosure for this sale can be found here. Insiders have sold 149,745 shares of company stock worth $21,210,998 over the last ninety days. Insiders own 1.80% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in DXCM. State Board of Administration of Florida Retirement System increased its position in shares of DexCom by 0.4% during the second quarter. State Board of Administration of Florida Retirement System now owns 120,747 shares of the medical device company’s stock valued at $11,469,000 after acquiring an additional 470 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of DexCom by 9.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,552 shares of the medical device company’s stock valued at $527,000 after buying an additional 471 shares in the last quarter. Metropolitan Life Insurance Co. NY lifted its stake in shares of DexCom by 7.6% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 6,879 shares of the medical device company’s stock valued at $653,000 after buying an additional 486 shares in the last quarter. Advisory Research Inc. lifted its stake in shares of DexCom by 17.2% during the 3rd quarter. Advisory Research Inc. now owns 4,084 shares of the medical device company’s stock valued at $584,000 after buying an additional 598 shares in the last quarter. Finally, Oppenheimer & Co. Inc. lifted its stake in DexCom by 23.8% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 3,282 shares of the medical device company’s stock worth $469,000 after purchasing an additional 630 shares in the last quarter. Hedge funds and other institutional investors own 99.05% of the company’s stock.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Further Reading: What is a Candlestick Chart?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.